EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Integrating early response biomarkers in pharmacokinetic models: A novel method to individualize the initial infliximab dose in patients with Crohn's disease

Abigail Samuels, Kei Irie iD, Tomoyuki Mizuno iD, Jack Reifenberg iD, Nieko Punt iD, Alexander A Vinks iD, Phillip Minar iD

Clinical and Translational Science · 2025

DOI: 10.1111/cts.70086 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Science, 2025. Verfasst von Abigail Samuels und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Department of Veterans Affairs, University of Cincinnati School of Medicine, Cincinnati, Ohio, USA. Hauptthemen laut MEDLINE: Crohn Disease, Infliximab, Models, Biological, Precision Medicine. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIDDK NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The use of model‐informed precision dosing to personalize infliximab has been shown to improve both the acquisition of concentration targets and clinical outcomes during maintenance. Current iterations of infliximab pharmacokinetic models include time‐varying covariates of drug clearance, however, not accounting for the expected improvements in the covariates can lead to indiscriminate use of higher infliximab doses and imprecise drug exposure. The aim was to identify changes in the four biomarkers associated with infliximab clearance (Xiong et al. model) and determine if integration of these dynamic changes would improve model performance during induction and early maintenance. We analyzed two cohorts of children receiving infliximab for Crohn's Disease. The E max method was used to assess time‐varying changes in covariates. Model performance (observed vs. predicted infliximab concentrations) was evaluated using median percentage error (bias) and median absolute percentage error (precision). The combined cohorts included 239 Crohn's disease patients. We found from baseline to dose 4, the maximum changes in weight, albumin, erythrocyte sedimentation rate, and neutrophil CD64 were 4.7%, +11.7%, −62.4%, and −26.5%, respectively. We also found the use of baseline covariates alone to forecast future trough concentration was inferior to the E max time‐varying method with a significant improvement observed in bias (doses 2, 3, and 4) and precision (doses 2 and 4). The integration of the four time‐varying biomarkers of drug clearance with pharmacokinetic modeling improved the accuracy and precision of the predictions. This novel strategy may be key to improving drug exposure, minimizing indiscriminate dosing strategies, and reducing healthcare costs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Crohn DiseaseInfliximabModels, BiologicalPrecision MedicineGastrointestinal AgentsHumansFemaleMaleBiomarkersChildAdolescentDose-Response Relationship, DrugDrug MonitoringTreatment Outcome

Substanzen

InfliximabBiomarkersGastrointestinal Agents

Autor:innen und Institutionen

  • Department of Internal Medicine, Department of Veterans Affairs, University of Cincinnati School of Medicine, Cincinnati, Ohio, USA.
  • Division of Translational and Clinical Pharmacology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
  • Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
  • University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
  • Medimatics, Maastricht, The Netherlands.
  • Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.

ORCID-Profile: Kei Irie, Tomoyuki Mizuno, Jack Reifenberg, Nieko Punt, Alexander A Vinks, Phillip Minar

Förderung

  • NIDDK NIH HHS

Zitieren

APA

Samuels, A., Irie, K., Mizuno, T., Reifenberg, J., Punt, N., Vinks, A. A., & Minar, P. (2025). Integrating early response biomarkers in pharmacokinetic models: A novel method to individualize the initial infliximab dose in patients with Crohn's disease. Clinical and Translational Science. https://doi.org/10.1111/cts.70086

Vancouver

Samuels A, Irie K, Mizuno T, Reifenberg J, Punt N, Vinks AA, et al. Integrating early response biomarkers in pharmacokinetic models: A novel method to individualize the initial infliximab dose in patients with Crohn's disease. Clinical and Translational Science. 2025. doi:10.1111/cts.70086

BibTeX
@article{Samuels2025,
  author = {Samuels, Abigail and Irie, Kei and Mizuno, Tomoyuki and Reifenberg, Jack and Punt, Nieko and Vinks, Alexander A and Minar, Phillip},
  title = {Integrating early response biomarkers in pharmacokinetic models: A novel method to individualize the initial infliximab dose in patients with Crohn's disease},
  journal = {Clinical and Translational Science},
  year = {2025},
  doi = {10.1111/cts.70086}
}
Kostenlos starten →